Iron for Restless Legs Syndrome

Verdict: Iron helps RLS when iron stores are low

For restless legs syndrome, iron works when iron stores are depleted, and intravenous ferric carboxymaltose (FCM) is the best-supported form. It is now a guideline first-line option once serum ferritin is at or below 75 ng/mL (or transferrin saturation under 20%), but it is not a cure-all and should follow a blood test rather than self-treatment.

A 🔵 A Moderate Evidence Published

🔬Why this grade7-layer evidence engine

The grade reflects consistent randomized evidence for a specific scenario rather than a blanket effect. A multicenter RCT of IV FCM (PMID 38625730, n=209) cut IRLS symptom scores more than placebo (LS-mean -8.0 vs -4.8; p=0.0036), and two meta-analyses agree: PMID 39326219 (n=537) found a pooled -6.03-point reduction (p=0.004), and the 2025 review PMID 40821477 (12 RCTs, n=511) found -5.28 points overall with a responder rate roughly doubled (RR 2.06).

It lands at moderate rather than strong because the benefit is uneven and partly partial. In the same large RCT the global-impression responder rate was not significantly better than placebo (35.5% vs 28.7%; p=0.30). Effect also depends on formulation: IV FCM is robust (subgroup -6.37; p=0.001) while iron sucrose did not reach significance (p=0.24) in PMID 40821477, and oral ferrous sulfate is only conditionally recommended in the 2025 AASM guideline (PMID 39324694).

Regulators and clinics support iron as essential (NIH ODS, FDA, EFSA, WHO), and specialty bodies are explicit for RLS: Mayo and Cleveland Clinic link low (especially brain) iron to symptoms, and the AASM/IRLSSG position recommends iron first-line when ferritin is at or below 75 ng/mL. Crucially, this is conditional on iron status, so fasting morning ferritin and TSAT testing should come first; the NHS notes most people get enough iron from diet, and unguided supplementation risks overload (e.g., hemochromatosis).

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.74
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published
Confidence
88%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L5 Clinical bodiesAuthoritative stance
0.78
L11 AI re-checkIndependent read
0.80
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.743
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial
PMID: 38625730 2024 RCT (double-blind) n = 209
Finding: FCM produced greater IRLS reduction than placebo (least-squares mean -8.0 vs -4.8; p=0.0036). Fewer FCM patients required additional RLS interventions (32.7% vs 59.4%; p=0.0002). CGI-I response not significantly different (35.5% vs 28.7%; p=0.2987). FCM well tolerated.
🟢 High quality ⚠️ Industry-funded Effect size: [object Object]
View on PubMed
Clinical efficacy and safety of IV ferric carboxymaltose in restless legs syndrome: A meta-analysis of 537 patients
PMID: 39326219 2024 統合分析 n = 537
Finding: Pooled IRLS reduction favoring IV FCM with weighted mean difference -6.03 points (p=0.004). SF-36 improved by +7.44 points (p=0.01). VAS RLS severity decreased significantly (p=0.003). Adverse events more common in FCM (notably nausea) but no significant differences in serious AEs.
🟢 High quality Effect size: [object Object]
View on PubMed
Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia
PMID: 34157632 2021 RCT (double-blind) n = 29
Finding: Significant IRLS improvement from baseline in FCM group (-13.47 +/- 7.38) vs placebo (+1.36 +/- 3.59). Sleep quality significantly improved. At week 52, 61% of FCM-treated subjects remained off RLS medications. No serious adverse events.
Effect size: [object Object]
View on PubMed
Efficacy and safety of iron supplements for restless leg syndrome, a systematic review, meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials
PMID: 40821477 2025 統合分析 n = 511
Finding: Overall IRLS reduction MD -5.28 (95% CI -7.66 to -2.90; p<0.0001; moderate certainty). IV iron MD -4.98 (95% CI -7.48 to -2.48; p<0.0001). FCM specifically MD -6.37 (95% CI -10.19 to -2.55; p=0.001). Iron sucrose not significant (p=0.24). Responder RR 2.06 (95% CI 1.49-2.84; p<0.0001; high certainty). Mostly mild AEs; no significant difference in discontinuation (p=0.08).
🟢 High quality Effect size: [object Object]
View on PubMed
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline
PMID: 39324694 2025 Other
Finding: STRONG recommendation (moderate certainty) for IV ferric carboxymaltose in patients with appropriate iron status. CONDITIONAL recommendation (moderate certainty) for ferrous sulfate (oral). Conditional/very-low certainty for IV iron dextran (LMW) and ferumoxytol. Iron studies should be drawn morning, fasting, with 24h iron-containing supplement washout. Aligns with IRLSSG consensus update on iron management for RLS.
🟢 High quality Mixed funding
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
NUTRIENT SUPPLEMENT source↗
L4b EU EFSA
Supportive
contributes to normal oxygen transport in the body source↗
L4c UK NHS
Cautious
You should be able to get all the iron you need from your daily diet. source↗
L4d TW TFDA / 衛福部
Supportive
育齡婦女及懷孕婦女每日建議攝取鐵量為15毫克,至懷孕第3期婦女則應增加每日攝取量至45毫克。 source↗
L4e WHO
Supportive
Daily oral iron and folic acid supplementation is recommended as part of antenatal care source↗
L5a NIH Office of Dietary Supplements
Supportive
Iron is an essential component of hemoglobin source↗
L5b Mayo Clinic
Supportive
iron deficiency can cause or worsen RLS source↗
L5c Cleveland Clinic
Supportive
Low iron levels in the brain are linked to restless legs syndrome source↗
L5e Specialty Society (condition-mapped)
Supportive
iron supplementation is recommended as a first-line treatment when serum ferritin is below 75 ng/mL source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-restless-legs-syndrome-INT-iron-001 繁體中文版 →